These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20369073)

  • 1. EUCAST breakpoints for antifungals.
    Rodríguez-Tudela JL; Arendrup MC; Cuenca-Estrella M; Donnelly JP; Lass-Flörl C
    Drug News Perspect; 2010 Mar; 23(2):93-7. PubMed ID: 20369073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Andes D; Diekema DJ; Espinel-Ingroff A; Sheehan D;
    Drug Resist Updat; 2010 Dec; 13(6):180-95. PubMed ID: 21050800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EUCAST technical note on Amphotericin B.
    Lass-Flörl C; Arendrup MC; Rodriguez-Tudela JL; Cuenca-Estrella M; Donnelly P; Hope W;
    Clin Microbiol Infect; 2011 Dec; 17(12):E27-9. PubMed ID: 22011310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EUCAST technical note on posaconazole.
    Arendrup MC; Cuenca-Estrella M; Donnelly JP; Hope W; Lass-Flörl C; Rodriguez-Tudela JL;
    Clin Microbiol Infect; 2011 Nov; 17(11):E16-7. PubMed ID: 21923779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).
    Cuenca-Estrella M; Arendrup MC; Chryssanthou E; Dannaoui E; Lass-Florl C; Sandven P; Velegraki A; Rodriguez-Tudela JL;
    Clin Microbiol Infect; 2007 Oct; 13(10):1018-22. PubMed ID: 17697001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
    Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
    Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
    Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods].
    Sancak B; Alp S; Hasçelik G; Arikan S
    Mikrobiyol Bul; 2009 Apr; 43(2):269-76. PubMed ID: 19621612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL
    Clin Microbiol Infect; 2005 Jun; 11(6):486-92. PubMed ID: 15882199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility-testing in Aspergillus species.
    Lass-Flörl C; Perkhofer S
    Mycoses; 2008 Sep; 51(5):437-46. PubMed ID: 18422914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
    Cuenca-Estrella M; Gomez-Lopez A; Gutierrez MO; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1062-5. PubMed ID: 18195057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
    Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW
    Drug Resist Updat; 2013 Dec; 16(6):81-95. PubMed ID: 24618110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broth medium for microdilution susceptibility tests of fluconazole and voriconazole.
    Barry A; Brown S; Traczewski M
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):407-10. PubMed ID: 12072930
    [No Abstract]   [Full Text] [Related]  

  • 17. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
    Lee SC; Lo HJ; Fung CP; Lee N; See LC
    J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between CLSI, EUCAST and Etest methodologies for amphotericin B and fluconazole antifungal susceptibility testing of Candida spp. clinical isolates.
    Claudino AL; Peixoto RF; Melhem MS; Szeszs MW; Lyon JP; Chavasco JK; Franco MC
    Pharmazie; 2008 Apr; 63(4):286-9. PubMed ID: 18468388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
    Marangon FB; Miller D; Giaconi JA; Alfonso EC
    Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.